LWM
ALXN

Lenox Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Lenox Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$7K Hold
68
– – ﹤0.01% 497
2020
Q1 		$6K Hold
68
– – ﹤0.01% 477
2019
Q4 		$7K Hold
68
– – ﹤0.01% 500
2019
Q3 		$6K Sell
68
-20
-23% -$2.25K ﹤0.01% 522
2019
Q2 		$11K Buy
+88
New +$11.3K ﹤0.01% 429

Other funds holding ALXN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Lenox Wealth Management's ALXN Position: Q2 2020 in Review

Lenox Wealth Management held its Alexion Pharmaceuticals (ALXN) position steady in Q2 2020 at 68 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #497.

Lenox Wealth Management first reported a position in ALXN in Q2 2019 and has held it in 5 quarters since. The position peaked at $11K in Q2 2019. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

  • Lenox Wealth Management held 68 shares of Alexion Pharmaceuticals worth $7K as of Q2 2020.
  • Lenox Wealth Management left its Alexion Pharmaceuticals share count unchanged in Q2 2020.
  • Alexion Pharmaceuticals made up ﹤0.01% of Lenox Wealth Management's portfolio in Q2 2020, its #497 holding.
  • Lenox Wealth Management first reported a position in Alexion Pharmaceuticals in Q2 2019 and has held it in 5 quarters since.
  • Lenox Wealth Management's Alexion Pharmaceuticals position peaked at $11K in Q2 2019.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Lenox Wealth Management's 13F filing for Q2 2020, filed 28 Jul 2020.